Market Overview

Deutsche Bank Reiterates Buy on Vertex Pharmaceuticals Following Press Release

Related VRTX
H.C. Wainwright Highlights Its Top Picks Ahead Of NACFC 2014
Fast Money Picks For September 26 - Pfizer Inc., The Dow Chemical Company And More

Following the press release issued earlier Tuesday morning by Vertex Pharmaceuticals (NASDAQ: VRTX), Deutsche Bank analyst, Robyn Karnauskas reiterated the firm's Buy rating and $103.00 price target for Vertex shares.

Karnauskas wrote, "Bottom line: We believe that this is the first step in Vertex platform treating entire cystic fibrosis population." Karnauskas based this on the belief that doctors will use the regimen for the high unmet need among the cystic fibrosis community for a viable treatment.

For a more detailed look into the press release see Why Is Vertex Pharmaceuticals Up More Than 50 Percent?

Latest Ratings for VRTX

DateFirmActionFromTo
Oct 2014Guggenheim SecuritiesInitiates Coverage onBuy
Sep 2014Deutsche BankMaintainsBuy
Sep 2014Deutsche BankMaintainsBuy

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings

Posted-In: Deutsche Bank Robyn KarnauskasAnalyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (VRTX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters